According to Fortune Business Insights, the global monoclonal antibodies in veterinary health market size was valued at USD 1.39 billion in 2025. The market is projected to grow from USD 1.66 billion in 2026 to USD 6.83 billion by 2034, exhibiting a CAGR of 19.38% during the forecast period. The market is gaining momentum as veterinary healthcare providers increasingly adopt targeted antibody-based treatments to manage various animal diseases and improve animal health outcomes.
The increasing prevalence of infectious, inflammatory, and chronic diseases among companion and livestock animals is supporting the adoption of monoclonal antibody-based therapies. These treatments are designed to target specific disease-related proteins or immune responses, offering more targeted therapeutic approaches than conventional treatment options.
Growing pet ownership and rising expenditure on companion animal healthcare are further contributing to market expansion. Pet owners are increasingly seeking advanced veterinary treatments to improve the quality of life and extend the lifespan of their animals.
The growing importance of companion animal health is creating new opportunities for monoclonal antibody manufacturers. Dogs and cats are increasingly receiving specialized veterinary care, including treatments for chronic conditions, allergic diseases, and inflammatory disorders.
Veterinary monoclonal antibody therapies are gaining attention because of their targeted mechanisms of action and potential to improve treatment outcomes. Increasing awareness among pet owners and veterinarians regarding advanced biologic treatments is expected to support market growth.
Advancements in biotechnology, antibody engineering, and protein development are supporting innovation in veterinary monoclonal antibody products. Pharmaceutical companies are investing in research and development to introduce targeted therapies for different animal species and disease conditions.
Improved diagnostic capabilities and growing investments in veterinary pharmaceutical research are also creating opportunities for the development of innovative antibody-based treatments.
Market participants are focusing on product innovation, regulatory approvals, research collaborations, and geographic expansion to strengthen their market positions. Increasing investments in animal health research are encouraging pharmaceutical companies to expand their veterinary biologics portfolios.
Emerging markets are also presenting growth opportunities due to improving veterinary healthcare infrastructure, increasing awareness of animal diseases, and rising expenditure on animal healthcare.
The global monoclonal antibodies in veterinary health market is characterized by the presence of established animal healthcare and pharmaceutical companies. Key players are focusing on developing innovative veterinary biologics, expanding product portfolios, and strengthening their global distribution networks.
Some of the major companies operating in the market include: